Mức độ angiopoietin-2, VEGF-A và VCAM-1 trong huyết tương như là các dấu hiệu của huyết áp cao do bevacizumab: CALGB 80303 và 90401 (Liên minh)

Garcia J, Hurwitz HI, Sandler AB et al (2020) Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev 86:102017 EMA summary of product characteristics (2017). https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf. Accessed 05 Oct 2020 FDA AVASTIN®prescribing information (2020). https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125085s332lbl.pdf. Accessed 05 Oct 2020 Quintanilha JCF, Wang J, Sibley AB et al (2020) Bevacizumab-induced hypertension and proteinuria: a genome-wide analysis of more than 1,000 patients. Eur J Cancer 138:S9–S10 Moslehi JJ (2016) Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med 375:1457–1467 Li M, Kroetz DL (2018) Bevacizumab-induced hypertension: clinical presentation and molecular understanding. Pharmacol Ther 182:152–160 Lazarus A, Keshet E (2011) Vascular endothelial growth factor and vascular homeostasis. Proc Am Thorac Soc 8:508–511 Ferroni P, Della-Morte D, Palmirotta R et al (2012) Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies. Curr Vasc Pharmacol 10:479–493 Ky B, Putt M, Sawaya H et al (2014) Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 63:809–816 Putt M, Hahn VS, Januzzi JL et al (2015) Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab. Clin Chem 61:1164–1172 Van Boxtel W, Bulten BF, Mavinkurve-Groothuis AMC et al (2015) New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide. Biomarkers 20:143–148 Kindler HL, Niedzwiecki D, Hollis D et al (2010) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28:3617–3622 Kelly WK, Halabi S, Carducci M et al (2012) Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 30:1534–1540 Innocenti F, Owzar K, Cox NL et al (2012) A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res 18:577–584 Hertz DL, Owzar K, Lessans S et al (2016) Pharmacogenetic discovery in CALGB (alliance) 90401 and mechanistic validation of a VAC14 polymorphism that increases risk of docetaxel-induced neuropathy. Clin Cancer Res 22:4890–4900 Nixon AB, Pang H, Starr MD et al (2013) Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (alliance). Clin Cancer Res 19:6957–6966 Innocenti F, Jiang C, Sibley AB et al (2018) Genetic variation determines VEGF-A plasma levels in cancer patients. Sci Rep 8:16332 Liu Y, Starr MD, Brady JC et al (2014) Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer. Cancer Med 3:580–591 Hatch AJ, Sibley AB, Starr MD et al (2016) Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Cancer Med 5:2249–2260 Liu Y, Starr MD, Bulusu A et al (2013) Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. Cancer Med 2:234–342 Barber MJ, Mangravite LM, Hyde CL et al (2010) Genome-wide association of lipid-lowering response to statins in combined study populations. PLoS ONE 5:e9763 Chu AY, Guilianini F, Barrat BJ, Nyberg F, Chasman DI, Ridker PM (2012) Pharmacogenetic determinants of statin-induced reductions in C-reactive protein. Circ Genom Precis Med 5:58–65 Kwiterovich PO, Virgil DG, Chu AY, Khouzami VA, Alaupovic P, Otvos JD (2013) Interrelationships between the concentration and size of the largest high-density lipoprotein subfraction and apolipoprotein C-I in infants at birth and follow-up at 2–3 months of age and their parents. J Clin Lipidol 7:29–37 Etheridge AS, Gallins PJ, Jima D et al (2020) A new liver expression quantitative trait locus map from 1,183 individuals provides evidence for novel expression quantitative trait loci of drug response, metabolic, and sex-biased phenotypes. Clin Pharmacol Ther 107:1383–1393 Innocenti F, Jiang C, Sibley AB et al (2019) An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance). Pharmacogenet Genom 29:123–131 R Core Team (2020) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria Ferrara N (2005) The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 64:209–231 Akwii RG, Sajib MS, Zahra FT, Mikelis CM (2019) Role of angiopoietin-2 in vascular physiology and pathophysiology. Cells 8:471 Kong DH, Kim YK, Kim MR, Jang JH, Lee S (2018) Emerging roles of vascular cell adhesion molecule-1 (VCAM-1) in immunological disorders and cancer. Int J Mol Sci 19:1057 Schlingemann RO, Van Hinsbergh VWM (1997) Role of vascular permeability factor/vascular endothelial growth factor in eye disease. Br J Ophthalmol 81:501–512 Möhle R, Green D, Moore MAS, Nachman RL, Rafii S (1997) Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 94:663–668 Verheul HMW, Hoekman K, Luykx-De Bakker S et al (1997) Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 3:2187–2190 Banks RE, Forbes MA, Kinsey SE et al (1998) Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 77:956–964 Gunsilius E, Petzer A, Stockhammer G et al (2000) Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology 58:169–174 Webb NJA, Myers CR, Watson CJ, Bottomley MJ, Brenchley PEC (1998) Activated human neutrophils express vascular endothelial growth factor (VEGF). Cytokine 10:254–257 Bocci G, Man S, Green SK et al (2004) Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res 64:6616–6625 Schmitz V, Vilanueva H, Raskopf E et al (2006) Increased VEGF levels induced by anti-VEGF treatment are independent of tumor burden in colorectal carcinomas in mice. Gene Ther 13:1198–1205 Eun SL, Oh MJ, Jae WJ et al (2007) The levels of circulating vascular endothelial growth factor and soluble Flt-1 in pregnancies complicated by preeclampsia. J Korean Med Sci 22:94–98 Blann AD (2003) How a damaged blood vessel wall contibutes to thrombosis and hypertension. Pathophysiol Haemost Thromb 33:445–448 Henry TD, Rocha-Singh K, Isner JM et al (2001) Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am Heart J 142:878–880 Lobov IB, Brooks PC, Lang RA (2002) Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 99:11205–11210 Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY (2001) Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear Factor-κB activation in endothelial cells. J Biol Chem 276:7614–7660 Belgore FM, Blann AD, Li-Saw-Hee FL, Beevers DG, Lip GYH (2001) Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension. Am J Cardiol 87:805–807 David S, Kümpers P, Lukasz A, Kielstein JT, Haller H, Fliser D (2009) Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/ pravastatin. J Hypertens 27:1641–1647 Palomo I, Marín P, Alarcón M et al (2003) Patients with essential hypertension present higher levels of sE-selectin and sVCAM-1 than normotensive volunteers. Clin Exp Hypertens 25:517–523 Desouza CA, Dengel DR, Macko RF, Cox K, Seals DR (1997) Elevated levels of circulating cell adhesion molecules in uncomplicated essential hypertension. Am J Hypertens 10:1335–1341 Nadar SK, Blann A, Beevers DG, Lip GYH (2005) Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)]. J Intern Med 258:336–343 Tsai WC, Li YH, Huang YY et al (2005) Plasma vascular endothelial growth factor as a marker for early vascular damage in hypertension. Clin Sci 109:39–43